Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Articles|February 2, 2020
- Pharmaceutical Technology-02-02-2020
- Volume 44
- Issue 2
Automated Neck Bander
The Pharmafill NB1, Series II from Deitz is an automated neck bander that can accommodate shrinkbands and full sleeve labels from .79–10 inches in length.
The Pharmafill NB1, Series II from Deitz is an automated neck bander that can accommodate shrinkbands and full sleeve labels from .79–10 inches in length, giving packaging professionals the ability to apply tamper-evident neck bands to a larger variety of glass and plastic bottles, jars, vials, dropper bottles, metal tins, and other containers in various sizes and shapes on the same neck banding machine.
The stainless-steel device operates at speeds up to 100 bottles per minute and comes equipped with a proprietary touch-screen HMI and a full-access interior for simplified rollstock replacement. The neck bander works with all heat-shrinkable banding materials from 25–123 mm in width applied over caps ranging from 14–76 mm in diameter. Vertical perforators, a photoelectric print registration, a companion heat tunnel, and a conveyor are also available with the device.
Articles in this issue
over 6 years ago
Pre-Clinical: Laying the Right Foundationover 6 years ago
Global Supply Issues Create Challengesover 6 years ago
The Call for a Rapid Responseover 6 years ago
ICH to Revise Quality Risk Management Guidelineover 6 years ago
Brexit: What Happens Next for Pharma?over 6 years ago
Of Serious Concern?over 6 years ago
Best Practices in Using Isolator Technologyover 6 years ago
Data Management Practicesover 6 years ago
Blister Packaging MachineRelated to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
PharmTech’s Weekly Roundup—September 25, 2026
3
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
4
CPHI Milan: USP Benchmarks Reshape Procurement Incentives
5